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Although the majority of patients with COVID-19 will experience mild 
to moderate symptoms and will recover fully, there is now increasing 
evidence that a significant proportion will experience persistent 
symptoms for weeks or months after the acute phase of the illness. 
These symptoms include, among others, fatigue, problems in 
breathing, lack of smell and taste, headaches, and also depression 
and anxiety. It has also become clear that the virus has lasting effects 
not only on the respiratory system but also on other parts of the body, 
including the heart, liver, and the nervous system. 
In this paper we present a protocol for a living systematic review that 
aims to synthesize the evidence on the prevalence and duration of 
symptoms and clinical features of post-acute COVID-19 and its long-
term complications. 
The living systematic review will be updated regularly, initially monthly 
with update cycles under continuous review as the pace of new 
evidence generated develops through the pandemic. We will include 
studies that follow up with COVID-19 patients who have experienced 
persistent mild, moderate or severe symptoms, with no restrictions 
regarding country, setting, or language. 
We will use descriptive statistics to analyse the data and our findings 
will be presented as infographics to facilitate transcription to lay 
audiences. Ultimately, we aim to support the work of policy makers, 
Open Peer Review
Reviewer Status  AWAITING PEER REVIEW
Any reports and responses or comments on the 
article can be found at the end of the article.
 
Page 1 of 5
F1000Research 2020, 9:1455 Last updated: 14 DEC 2020
Corresponding author: Charitini Stavropoulou (C.Stavropoulou@city.ac.uk)
Author roles: Michelen M: Data Curation, Formal Analysis, Investigation, Methodology, Validation, Writing – Review & Editing; Sigfrid L: 
Funding Acquisition, Methodology, Validation, Writing – Review & Editing; Manoharan L: Data Curation, Formal Analysis, Methodology, 
Validation, Writing – Review & Editing; Elkheir N: Data Curation, Investigation, Methodology, Validation, Writing – Review & Editing; 
Hastie C: Investigation, Validation, Writing – Review & Editing; O'Hara M: Investigation, Validation, Writing – Review & Editing; Suett JC: 
Investigation, Methodology, Validation, Writing – Review & Editing; Cheng V: Data Curation, Formal Analysis, Investigation, 
Methodology, Validation, Writing – Review & Editing; Burls A: Investigation, Validation, Writing – Review & Editing; Foote C: 
Investigation, Validation, Writing – Review & Editing; Stavropoulou C: Conceptualization, Data Curation, Formal Analysis, Investigation, 
Methodology, Project Administration, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing
Competing interests: No competing interests were disclosed.
Grant information: This work was supported by the Department for International Development and Wellcome [215091] and the Bill and 
Melinda Gates Foundation [OPP1209135].  
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2020 Michelen M et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Michelen M, Sigfrid L, Manoharan L et al. What are the long-term symptoms and complications of COVID-
19: a protocol for a living systematic review [version 1; peer review: awaiting peer review] F1000Research 2020, 9:1455 
https://doi.org/10.12688/f1000research.27284.1
First published: 14 Dec 2020, 9:1455 https://doi.org/10.12688/f1000research.27284.1 
practitioners, and patients when planning rehabilitation for those 
recovering from COVID-19. 
The protocol has been registered with PROSPERO (CRD42020211131, 
25/09/2020).
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Background
More than six months into the pandemic, our knowledge 
around COVID-19 continues to develop rapidly. The range of 
documented COVID-19 infections vary from asymptomatic 
to severe, but the vast majority of patients experience mild to 
moderate symptoms and do not require hospitalisation1. We 
have previously conducted a rapid review of the literature to 
identify which symptoms and signs might differentiate mild 
and moderate from severe COVID-192. Since then, and as 
more data are being gathered, there is increasing evidence of a 
“long-tail” of COVID-19 illness, but limited information about 
the range and duration of symptoms experienced3 or longer term 
health complications. A community app developed at King’s 
College London, which tracks self-reported symptoms, has 
shown that about one in ten will be sick for three weeks or 
more (https://covid.joinzoe.com/post/covid-long-term). Some 
individuals with COVID-19 have reported “fatigue, headaches 
and tingling nerves” that lasted months after symptom onset4. 
A recent longitudinal cohort of 143 patients followed after 
hospitalisation from COVID-19 in Italy reported that 87% had at 
least one ongoing symptom, most (55%) reporting three or more, 
at 60 day follow up. Fatigue (53%), dyspnoea (43%), joint pain 
(27%) and chest pain (22%) were the most common ongoing 
symptoms5, but there is a variety of other symptoms and 
complications that have been reported including neurocogni-
tive difficulties, muscle pains and weakness, gastrointestinal 
upset, rashes, metabolic disruption, thromboembolic conditions 
and mental health conditions6. A prolonged course of illness 
has also been reported among people with mild COVID-19 who 
did not require hospitalisation3,7,8.
The evidence to date remains fragmented as to the onset of 
symptoms and clinical features, how long symptoms may last, 
how this relates to the severity of the initial illness, and further 
lasting impacts to health. A better understanding of patients’ 
projected recovery from COVID-19 is helpful to patients, 
healthcare professionals, policymakers and commissioners. 
The clinical management of persisting symptoms of COVID-19 
has started to be addressed in the clinical literature6 and NHS 
England has issued guidance for the multisystem needs of 
patients recovering from COVID-199. Our findings could help 
identify people requiring additional rehabilitation services and, 
where necessary, specialist referral to establish a secondary 
cause of their symptoms. Our findings will also be relevant to 
organisations such as NHS England, which have recently 
launched an online COVID-19 rehab service supporting patients 
suffering long-term effects of the disease (https://www.your-
covidrecovery.nhs.uk/) or the British Society of Immunologists, 
which recently released a briefing note recommending research 
into the long-term immunological health consequences of 
COVID-1910.
The aim of this review is to synthesize the evidence on the 
prevalence and duration of symptoms and clinical features of 
post-acute COVID-19 and its long-term complications. This will 
inform clinical and public health management, prevention and 
rehabilitation policies.
Methods
To address the aim of this study we will conduct a living 
systematic review (LSR). LSRs are used in areas where research 
evidence is emerging rapidly, current evidence is uncertain, 
and new research may influence policy or practice decisions11. 
These are all features of COVID-19 research, where much about 
the long-term effects of the disease are still unknown and policy 
makers are calling for more evidence. The review will be 
initially updated monthly, with update cycles under continuous 
review as the pace of new evidence generated develops through 
the pandemic. We aim to continue to update the review for up 
to two years. Our study methodology has been developed and 
strengthened through consultation with Long Covid Support 
(a patient support network). 
Inclusion/exclusion criteria
We will include studies that meet the follow criteria:
-      Studies of patients with COVID-19 who have persistent 
mild, moderate or severe symptoms as defined by the 
article authors
-      Studies following up with COVID-19 patients
-      Peer reviewed articles published since 1st January 2020
-      No restriction regarding country, setting or language
We will exclude:
-      Studies that focus only on acute COVID-19
-      Editorials and opinion papers
Search strategy
A search of the following databases will be conducted: 
Pubmed and CINAHL through the EBSCO database host for 
general health peer-reviewed articles and Global Health for 
global peer-reviewed articles through the Ovid database host. 
In addition, we will search Cochrane for relevant systematic 
reviews and Google Scholar for grey literature including 
pre-prints. We will also look at the WHO Global Research 
Database on COVID-19 and LitCOVID as two databases that 
bring together evidence on COVID-19 from a worldwide 
dataset. Finally, we will contact experts in the field and use 
social media to identify relevant studies.
Data will be managed using the review software Rayyan12.
Key search terms
We will search using controlled subject headings and keywords 
of the following concepts: Terms related to 1) COVID-19 OR 
COVID OR SARS-CoV-2; 2) symptoms OR clinical features 
OR signs OR characteristics OR sequelae OR complications; 
3) long-term OR post-acute OR long-tail OR persistent OR 
chronic COVID OR long COVID OR post discharge OR 
prolonged symptoms OR long haul. The search terms were 
piloted on Pubmed and CINAHL through the EBSCO database 
host the week starting 14th September 2020 to ensure that 
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recent high profile research articles on long covid were included. 
No important studies were missed.
An example is shown below:
MEDLINE Search
S1. COVID-19 OR OR covid OR SARS-CoV-2. ab 31,903
S2. symptom* OR “clinical features” OR signs OR 
characteristic* OR sequelae OR complication*.ab 188,243
S3. “long-term Covid” OR long-term N2 consequence* 
OR “long-term impact” OR “long-term effect” OR “post-
acute” OR long-tail OR persist* OR “chronic-COVID” 
OR “long-COVID” OR post-discharge OR postdischarge 
OR “prolonged symptom” OR “long-haul” .ab
25,598
S4. S1 AND S2 AND S3 309
Screening
Initial screening of titles and abstracts as well as full text 
screening against the inclusion criteria will be done by two 
reviewers. Disagreements for inclusion will be resolved by 
consensus. Where disagreements cannot be resolved, a third 
researcher will review the papers to make the final decision.
Critical appraisal checklist
We will be using the Hoy et al. checklist13 to critically appraise 
the studies included in the review.
Data extraction
The following information will be extracted from each study 
based on the extraction form used for our initial review2: study 
aim, country of study, setting, method, study design and 
population size and characteristics, types and frequency of 
symptoms reported, onset and duration of symptoms. Data 
extraction will be performed by one reviewer and checked by 
a second reviewer. Disagreements will be resolved through 
discussion and consensus.
Data analysis
We will use descriptive statistics to summarise the types of 
symptoms, their frequency and duration. We will perform 
subgroup analysis on the basis of age, sex, comorbidities and 
severity of the disease. The data will be presented as infographics 
to facilitate transcription to lay audiences.
Protocol registration
This protocol report is structured according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
Protocols (PRISMA-P) statement guidelines14, was registered 
with PROSPERO (CRD42020211131, 25 September 2020). The 
protocol will be updated as we progress with the living review 
as and if needed. CS is the guarantor for this study.
Data availability
Underlying data
No underlying data are associated with this article.
Reporting guidelines
Figshare: PRISMA-P checklist for “What are the long-term 
symptoms and complications of COVID-19: a protocol for a 
living systematic review”. https://doi.org/10.25383/city.13187456.
v115.
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